Clinical Quiz: Aspirin Therapy After Desensitization in AERD

Credit: HCPLive

Aspirin-exacerbated respiratory disease (AERD), also known as Samter’s triad, is a challenging condition affecting 7–10% of adults with asthma and up to 30% of patients with severe chronic rhinosinusitis with nasal polyposis (CRSwNP). AERD is characterized by persistent upper and lower airway inflammation, often leading to severe nasal polyposis, recurrent sinus infections, and difficult-to-control asthma. One of the key treatment strategies for AERD is aspirin desensitization, followed by long-term aspirin therapy to maintain symptom control.

The GRADE guidelines provide updated recommendations on the role of aspirin therapy after desensitization in AERD, highlighting its ability to reduce the need for repeated surgeries, slow polyp regrowth, and improve overall respiratory function. However, aspirin therapy is not without risks, as gastrointestinal side effects, bleeding concerns, and adherence challenges can impact patient outcomes. Identifying appropriate candidates for desensitization and determining optimal aspirin dosing are crucial for maximizing therapeutic benefit.

In this quiz, you will explore the latest guideline recommendations for aspirin therapy in AERD, including efficacy data, risk mitigation strategies, and patient selection criteria. Are you equipped with the latest knowledge on aspirin therapy in AERD? Let’s put it to the test.